Non‐ApHCM patients with elevated IL‐6 levels exhibited the highest myocardial fibrosis burden and the worst clinical outcomes, likely reflecting a complex interplay between genetic predisposition and chronic inflammation. Here, IL6 is linked to Myocardial fibrosis.